Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease

JAMA

Volumn 281, Issue 15, 1999, Pages 1407-1414

  Vorchheimer, David A ^a,b   Badimon, Juan Jose ^a,b   Fuster, Valentin ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; MONOCLONAL ANTIBODY; PEPTIDE; TIROFIBAN; VITRONECTIN;

ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; DRUG SAFETY; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVASCULARIZATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOGENESIS; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0033590957     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.15.1407     Document Type: Article

References (64)

1. WHO-MONICA Project Myocardial infarction and coronary deaths in the World Health Organizatior MONICA project: registration procedures, event rates and case fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583-612.
2. Falk E. Coronary thrombosis: pathogenesis and clinical manifestations. Am J Cardiol. 1991;68:288-358.
3. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:310-318.
4. Dewood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
5. Bresnahan DR, Davis DR, Holmes DR Jr, et al. Angiographic occurrence and clinical correlates of intraluminal coronary artery thrombus: role of unstable angina. J Am Coll Cardiol. 1985;6:285-289.
6. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med. 1992:326:287-291.
7. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J. 1983;50:127-134.
8. Mertini PA, Bauer KA, Oltrona L, et al. Persistent activation of the coagulation system in unstable angina and myocardial infarction. Circulation. 1994;90: 61-68.
9. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Chesebro JH, Badimon L. Thrombogenicity of human arterial wall: implications for vascular interventions. J Am Coll Cardiol. 1994;23:1562-1569.
10. Hynes RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell. 1992;69:11-25.
11. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
12. Marcus AJ. Platelet activation. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia. Pa: Lippincott-Raven; 1996: 607-637.
13. Plow EF, McEver RP, Coller BS, Woods VL Jr, Marguerle GA, Ginsberg MH. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood. 1985;66:724-727.
14. Plow EF, Marguerie C, Ginsberg M. Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol. 1987;36:4035-4040.
15. Coller BS, Seligsohn U, Peretz H, Newman PJ. Glanzmann thrombasthenia: new insights from an historical perspective. Semin Hematol. 1994;31:301-311.
16. Geirge JN, Caen JP, Nurden JT. Glanzmann thrombasthenia: the spectrum of clinical disease. Blood. 1990; 75:1383-1395.
17. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
18. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 1994;308:159-168.
19. Cairns JA, Lewis D Jr, Meade TW, Sutton GC, Theroux P. Antithrombotic agents in coronary artery disease. Chest. 1998;114(suppl 5):611S-633S.
20. Bamathan ES, Schwartz JS, Taylor L, et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation. 1987;76:125-134.
21. Coller BS. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GP IIb/ IIIa receptors as antithrombotic therapy. Eur Heart J. 1995;16(suppl L):11-15.
22. Fitzgerald GA, Patrono C. Antiplatelet drugs. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular Thrombosis. 2nd ed. Philadelphia, Pa: Lippincott Raven; 1998:121-140.
23. The EPIC Investigators. Use of a monoclonal antibody directed against trie platelet glycoprotein IIb/ IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
24. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation. 1995; 91:2882-2890.
25. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994; 323:881-886.
26. 3 blockade with percutaneous coronary intervention. JAMA. 1997;278: 479-484.
27. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
28. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
29. The EPISTENT Investigators. Randomized placebocontrolled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
30. Brener SJ, Barr LA, Burchenal JEB, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734-741.
31. The IMPACT-II Investigators. Randomised placebo-controlled trial of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422-1428.
32. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tiroflban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
33. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. J Am Coll Cardiol. 1997;30:149-156.
34. 2+ on GPIIb/IIIa interactions with integrilin: enhanced CPIIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:1488-1494.
35. The PURSUIT Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
36. The PRISM-Plus Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. W Engl J Med. 1998;338:1488-1497.
37. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation. 1998;97:2386-2395.
38. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
39. Harrington RA, Lincoff AM, Berdan LG, et al. Maintenance of clinical benefit at 6 months in patients treated with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event [abstract]. Circulation. 1998; 98(suppl I):359.
40. Vaughn DE, Van Houtte E, Declerck PJ, Collen D. Streptokinase-induced platelet aggregation: prevalence and mechanism. Circulation. 1991;84:84-91.
41. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observations in animals and humans. Circulation. 1997;95:1755-1759.
42. Antman EM, Guigliano RP, McCabe CH, et al. Abciximab (ReoPro) potentiates thrombolysis in ST segment elevation myocardial infarction: results of TIMI 14 trial [abstr]. J Am Coll Cardiol. 1998;31:191.
43. Ohman EM, Kleiman NA, Gacioch G, et al, for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose-ranging trial. Circulation. 1997;95:846-854.
44. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa Inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol. 1998;32:2003-2010.
45. Ohman EM. Preliminary results of the SPEED pilot trial. In: Program and abstracts of the 20th Congress of the European Society of Cardiology; August 22-26, 1998; Vienna, Austria.
46. Hamm CW, Heeschen C, Goldmann B, et al. Troponin T predicts the benefit of abciximab in patients with unstable angina in the CAPTURE study [abstract]. Eur Heart J. 1998;19(suppl):117.
47. Peterson JC, Lauer MA, Sapp SK, et al. Heparin is required for clinical benefit of GP IIb/IIIa inhibitor eptifibatide in acute coronary syndromes: insights from the PURSUIT trial, [abstract]. Circulation. 1998;98 (suppl I):360.
48. Boehner JD, Kereiakes DJ, Navetter FI, Califf RM, Topol EJ, for the EPIC Investigators, Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. AM J Cardiol. 1994;74:1166-1770.
49. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation. 1997;96:3810.
50. Berkowitz SD, Harrington RA, Rund MM, et al. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation. 1997;95:809-813.
51. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet. 1999;353:227-231.
52. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol. 1993;5:864-868.
53. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/ human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest. 1996;98: 863-874.
54. Ellis SG, Serruys PW, Popma JJ, et al. Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? the final ERASER results [abstract]. Circulation. 1997;96(suppl I):87.
55. Coller BS. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost. 1997;78:730-735.
56. Madan M, Kereiakes OJ, Rund M, et al. Abciximab readministration for coronary interventions: is it safe? [abstract]. Circulation. 1997;96(suppl I):162.
57. Tcheng JE, Kereiakes DJ, George BS, et al. Safety of readministration of abciximab: interim results of the ReoPro Readministration Registry [abstract]. J Am Coll Cardiol. 1998;31:55A.
58. Badimon JJ, Meyer B, Feigen LP, et al. Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist. Eur J Clin Invest. 1997;27:568-574.
59. Kereiakes DJ, Kleiman N, Ferguson JJ, et al. Sustained platelet glycoprotein IIb/IIIa blockade with oral Xemilofiban in 170 patients after coronary stent deployment. Circulation. 1997;96:1117-1121.
60. Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by fradafiban, a non-peptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men. Circulation. 1997;96:1130-1138.
61. Cannon CP, McCabe CH, Borzak S, et al, and the TIMI 12 Investigators. A randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome. Circulation. 1998;97:340-349.
62. Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/IIIa antagonists: the present challenge is safety. Circulation. 1998;97:312-314.
63. Cannon C. Preliminary results of the OPUS-TIMI 16 trial. In: Program and abstracts of the 48th Annual Scientific Sessions of the American College of Cardiology; March 10, 1999; New Orleans, La.
64. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation. 1997;96:3828-3832.